JP2007518738A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007518738A5 JP2007518738A5 JP2006549523A JP2006549523A JP2007518738A5 JP 2007518738 A5 JP2007518738 A5 JP 2007518738A5 JP 2006549523 A JP2006549523 A JP 2006549523A JP 2006549523 A JP2006549523 A JP 2006549523A JP 2007518738 A5 JP2007518738 A5 JP 2007518738A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydroxy
- alkylenyl
- ethyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 229910052757 nitrogen Inorganic materials 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000005466 alkylenyl group Chemical group 0.000 claims 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- -1 hydroxy, amino Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- JRRKWFRTDFOWAB-SANMLTNESA-N 5-[(1r)-2-[2-[4-[4-(2-amino-2-methylpropoxy)anilino]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C1=CC(OCC(C)(N)C)=CC=C1NC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 JRRKWFRTDFOWAB-SANMLTNESA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- JAZUDZQWDOBUNH-VWLOTQADSA-N 5-[(1r)-2-[2-[4-[3-(2-aminoethyl)-4-methoxyanilino]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C1=C(CCN)C(OC)=CC=C1NC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 JAZUDZQWDOBUNH-VWLOTQADSA-N 0.000 claims 1
- GDLGSGUEBOBZBM-VWLOTQADSA-N 5-[(1r)-2-[2-[4-[4-(2-aminoethyl)anilino]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C1=CC(CCN)=CC=C1NC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 GDLGSGUEBOBZBM-VWLOTQADSA-N 0.000 claims 1
- CUJSRMHESAYKCR-MHZLTWQESA-N 5-[(1r)-2-[2-[4-[4-[2-(dimethylamino)ethyl]anilino]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C1=CC(CCN(C)C)=CC=C1NC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 CUJSRMHESAYKCR-MHZLTWQESA-N 0.000 claims 1
- RWBDYOUHRBKWMC-LJAQVGFWSA-N 8-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[4-(2-piperazin-1-ylethoxy)anilino]phenyl]ethylamino]ethyl]-1h-quinolin-2-one Chemical compound C([C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)NCCC(C=C1)=CC=C1NC(C=C1)=CC=C1OCCN1CCNCC1 RWBDYOUHRBKWMC-LJAQVGFWSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 0 *C(Cc(cc1)ccc1Nc1ccc(*)c(*)c1)(NC(*c1c2cc(*)c(*)c1*)C2O)S Chemical compound *C(Cc(cc1)ccc1Nc1ccc(*)c(*)c1)(NC(*c1c2cc(*)c(*)c1*)C2O)S 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53578404P | 2004-01-12 | 2004-01-12 | |
| US60/535,784 | 2004-01-12 | ||
| PCT/US2005/000810 WO2005070872A1 (en) | 2004-01-12 | 2005-01-11 | Aryl aniline derivatives as beta2 adrenergic receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007518738A JP2007518738A (ja) | 2007-07-12 |
| JP2007518738A5 true JP2007518738A5 (enExample) | 2008-02-07 |
| JP5041814B2 JP5041814B2 (ja) | 2012-10-03 |
Family
ID=34806964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549523A Expired - Fee Related JP5041814B2 (ja) | 2004-01-12 | 2005-01-11 | β２アドレナリン作用性レセプターアゴニストとしてのアリールアニリン誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7622467B2 (enExample) |
| EP (1) | EP1706371B1 (enExample) |
| JP (1) | JP5041814B2 (enExample) |
| KR (1) | KR20070000466A (enExample) |
| CN (1) | CN1910137B (enExample) |
| AR (1) | AR047098A1 (enExample) |
| AT (1) | ATE504559T1 (enExample) |
| AU (1) | AU2005206510A1 (enExample) |
| BR (1) | BRPI0506823A (enExample) |
| CA (1) | CA2551821A1 (enExample) |
| DE (1) | DE602005027307D1 (enExample) |
| ES (1) | ES2364450T3 (enExample) |
| IL (1) | IL176549A0 (enExample) |
| MA (1) | MA28304A1 (enExample) |
| NO (1) | NO20063620L (enExample) |
| NZ (1) | NZ548196A (enExample) |
| RU (1) | RU2370490C2 (enExample) |
| TW (1) | TW200531692A (enExample) |
| WO (1) | WO2005070872A1 (enExample) |
| ZA (1) | ZA200605720B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6200134B1 (en) | 1998-01-20 | 2001-03-13 | Kerr Corporation | Apparatus and method for curing materials with radiation |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US7182597B2 (en) | 2002-08-08 | 2007-02-27 | Kerr Corporation | Curing light instrument |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| US7402673B2 (en) * | 2004-06-03 | 2008-07-22 | Theravance, Inc. | Diamine β2 adrenergic receptor agonists |
| US7317023B2 (en) * | 2004-07-21 | 2008-01-08 | Theravance, Inc. | Diaryl ether β2 adrenergic receptor agonists |
| WO2006031556A2 (en) * | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Amidine substituted aryl aniline compounds |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| CN101137625A (zh) * | 2005-01-11 | 2008-03-05 | 葛兰素集团有限公司 | β2肾上腺素能激动剂的肉桂酸盐 |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| US8113830B2 (en) | 2005-05-27 | 2012-02-14 | Kerr Corporation | Curing light instrument |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| TW200745067A (en) * | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| PE20080361A1 (es) | 2006-04-21 | 2008-06-03 | Novartis Ag | Compuestos derivados de purina como activadores del receptor de adenosina a2a |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| ES2306595B1 (es) * | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
| ES2320961B1 (es) * | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
| EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
| UY31905A (es) | 2008-06-18 | 2010-01-29 | Astrazeneca Ab | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. |
| US8236786B2 (en) * | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
| EP2379507B1 (en) | 2008-12-30 | 2013-10-16 | Pulmagen Therapeutics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
| EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
| KR20140014184A (ko) | 2011-02-25 | 2014-02-05 | 아이알엠 엘엘씨 | Trk 억제제로서의 화합물 및 조성물 |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| CN118416038B (zh) * | 2024-04-28 | 2024-11-12 | 中国海洋大学 | 2-(2-甲基丙氧基)苯胺在制备治疗炎症性疾病的药物中的应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1250450B (de) | 1962-03-31 | 1967-09-21 | Deutsche Gold- und Silber-Scheideanstalt vormals Roessler, Frankfurt/M | Verfahren zur Herstellung von Aminoalkoholen sowie deren Säureadditionssalzen und quartären Ammoniumverbindungen |
| AT310146B (de) | 1971-04-26 | 1973-09-25 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen |
| CH545764A (enExample) | 1971-07-27 | 1974-02-15 | ||
| BE794414A (fr) | 1972-01-25 | 1973-07-23 | Sandoz Sa | Nouveaux amino-alcools, leur preparation et leur application comme medicament |
| FR2266497B1 (enExample) | 1974-04-03 | 1977-11-04 | Roussel Uclaf | |
| JPS5913510B2 (ja) | 1975-12-26 | 1984-03-30 | オオツカセイヤク カブシキガイシヤ | カルボスチリルユウドウタイノセイゾウホウ |
| JPS5283619A (en) | 1976-01-01 | 1977-07-12 | Yamanouchi Pharmaceut Co Ltd | Alpha-substituted aminomethyl benzyl alcohol derivative |
| JPS609713B2 (ja) | 1976-10-08 | 1985-03-12 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| GB8507942D0 (en) | 1985-03-27 | 1985-05-01 | Beecham Group Plc | Compounds |
| EP0233686A3 (en) | 1986-01-11 | 1989-05-03 | Beecham Group Plc | Bis phenyl ethanol amines and bis phenyoxypropanolamines having a beta-agonist activity |
| US5223614A (en) * | 1987-12-19 | 1993-06-29 | Boehringer Ingelheim Gmbh | New quaternary ammonium compounds, their preparation and use |
| US4894219A (en) | 1988-03-29 | 1990-01-16 | University Of Florida | Beta-agonist carbostyril derivatives, assay method and pharmacological composition |
| US5434304A (en) * | 1990-09-26 | 1995-07-18 | Aktiebolaget Astra | Process for preparing formoterol and related compounds |
| NO179246C (no) * | 1991-11-20 | 1996-09-04 | Sankyo Co | Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav |
| GB9405019D0 (en) * | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| US5808080A (en) * | 1996-09-05 | 1998-09-15 | Eli Lilly And Company | Selective β3 adrenergic agonists |
| US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| GB9713819D0 (en) * | 1997-06-30 | 1997-09-03 | Glaxo Group Ltd | Method of reducing the systemic effects of compounds |
| US6713651B1 (en) * | 1999-06-07 | 2004-03-30 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6362371B1 (en) * | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| US20020143034A1 (en) * | 1998-12-30 | 2002-10-03 | Fujisawa Pharmaceutical Co. Ltd. | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| AU6050000A (en) | 1999-07-22 | 2001-02-13 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| CN1426401A (zh) * | 2000-04-27 | 2003-06-25 | 贝林格尔英格海姆法玛公司 | 新的长效倍他米美类药物(betamimetics)其制备方法,及其作为药物组合物的用途 |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| IL154928A0 (en) * | 2000-11-10 | 2003-10-31 | Lilly Co Eli | 3-substituted oxindole beta 3 agonists |
| GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) * | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| ATE381537T1 (de) * | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| RU2312854C2 (ru) | 2001-09-14 | 2007-12-20 | Глаксо Груп Лимитед | Производные фенэтаноламина для лечения респираторных заболеваний |
| WO2003042160A1 (en) * | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| US20030229058A1 (en) | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
| EP1507754A1 (en) * | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
| NZ537206A (en) | 2002-06-27 | 2007-06-29 | Astellas Pharma Inc | Aminoalcohol derivatives |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| TW200409746A (en) * | 2002-07-26 | 2004-06-16 | Theravance Inc | Crystalline β2 adrenergic receptor agonist |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| JP4767842B2 (ja) | 2003-04-01 | 2011-09-07 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
| EP1622875B1 (en) | 2003-05-08 | 2009-12-02 | Theravance, Inc. | Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist |
| US7556785B2 (en) * | 2003-05-12 | 2009-07-07 | United Phosphorus, Ltd. | Apparatus and method for rapid and continuous generation of phosphine gas |
| TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| US7402673B2 (en) * | 2004-06-03 | 2008-07-22 | Theravance, Inc. | Diamine β2 adrenergic receptor agonists |
| US7317023B2 (en) * | 2004-07-21 | 2008-01-08 | Theravance, Inc. | Diaryl ether β2 adrenergic receptor agonists |
| WO2006031556A2 (en) * | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Amidine substituted aryl aniline compounds |
-
2004
- 2004-12-30 TW TW093141433A patent/TW200531692A/zh unknown
-
2005
- 2005-01-11 JP JP2006549523A patent/JP5041814B2/ja not_active Expired - Fee Related
- 2005-01-11 CN CN2005800022796A patent/CN1910137B/zh not_active Expired - Fee Related
- 2005-01-11 AT AT05711348T patent/ATE504559T1/de not_active IP Right Cessation
- 2005-01-11 AR ARP050100092A patent/AR047098A1/es unknown
- 2005-01-11 BR BRPI0506823-1A patent/BRPI0506823A/pt not_active IP Right Cessation
- 2005-01-11 CA CA002551821A patent/CA2551821A1/en not_active Abandoned
- 2005-01-11 RU RU2006129312/04A patent/RU2370490C2/ru not_active IP Right Cessation
- 2005-01-11 AU AU2005206510A patent/AU2005206510A1/en not_active Abandoned
- 2005-01-11 ES ES05711348T patent/ES2364450T3/es not_active Expired - Lifetime
- 2005-01-11 EP EP05711348A patent/EP1706371B1/en not_active Expired - Lifetime
- 2005-01-11 KR KR1020067015602A patent/KR20070000466A/ko not_active Withdrawn
- 2005-01-11 WO PCT/US2005/000810 patent/WO2005070872A1/en not_active Ceased
- 2005-01-11 US US11/033,198 patent/US7622467B2/en active Active
- 2005-01-11 NZ NZ548196A patent/NZ548196A/xx unknown
- 2005-01-11 DE DE602005027307T patent/DE602005027307D1/de not_active Expired - Lifetime
-
2006
- 2006-06-26 IL IL176549A patent/IL176549A0/en unknown
- 2006-07-11 ZA ZA200605720A patent/ZA200605720B/xx unknown
- 2006-07-24 MA MA29204A patent/MA28304A1/fr unknown
- 2006-08-09 NO NO20063620A patent/NO20063620L/no not_active Application Discontinuation
-
2009
- 2009-10-06 US US12/574,066 patent/US7994165B2/en not_active Expired - Fee Related
-
2011
- 2011-06-28 US US13/170,386 patent/US20120071654A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007518738A5 (enExample) | ||
| JP2007505931A5 (enExample) | ||
| JP2008501705A5 (enExample) | ||
| RU2006129312A (ru) | Производные ариланилина в качестве агонистов 2 адренергического рецептора | |
| ES2399179T3 (es) | Tratamiento de enfermedad respiratoria | |
| JP2008507532A5 (enExample) | ||
| JP2010511626A5 (enExample) | ||
| JP2008512470A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| JP2008525466A5 (enExample) | ||
| CA2464223C (en) | Quarternary ammonium compounds and their use as antimuscarinic agents | |
| JP2012524111A5 (enExample) | ||
| JP2006517939A5 (enExample) | ||
| JP2009528371A5 (enExample) | ||
| JP2012500260A5 (enExample) | ||
| JP2005533860A5 (enExample) | ||
| JP2013530179A5 (enExample) | ||
| CA2575874A1 (en) | Crystalline form of a biphenyl compound | |
| JP2006182786A5 (enExample) | ||
| JP2015521167A5 (enExample) | ||
| RU2008145971A (ru) | Производные 2-тиоксантина, действующие в качестве ингибиторов мро | |
| BRPI0707559B1 (pt) | polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos | |
| JP2011507878A5 (enExample) | ||
| JP2009534404A5 (enExample) | ||
| JP2007269797A5 (enExample) |